International Stem Cell Corporation (ISCO) and a new firm to be formed by John Mauldin announced the formation of a new joint marketing venture to launch a line of skincare products developed by ISCO’s wholly-owned subsidiary, Lifeline Skin Care, Inc.
Mauldin, a significant marketing talent, is president of Millennium Wave Investments and author of an economic letter that goes to over 1.5 million readers.
“This is a truly revolutionary approach to skin care. Early test results are very promising and I am excited to be associated with a company of the scientific reputation of International Stem Cell Corporation and their world-renowned staff.”
Lifeline Skin Care’s products have been in active development for well over a year and involve a unique high-technology, patent pending formulation for skin rejuvenation crèmes, developed using ISCO’s proprietary “parthenogenetic” stem cells that do not require the use of fertilized embryos. The product was discovered during ISCO’s therapeutic stem cell research that revealed the stem cell’s potential applications in skin cell rejuvenation.
Part of the discovery included developing a way to surround the proteins from the stem cells with a nanovesicle allowing for extended shelf life and enhanced delivery of the product to the skin. Independent third party testing indicates that the crèmes (one for day and one for nighttime application) have significant positive effects on the look and feel of the skin.
“This represents an amazing leap forward in the combination of a variety of cutting edge technologies to yield products that have the potential to find significant consumer acceptance. The anti-aging market is extremely large, and Lifeline Skin Care is offering something completely new and different. We are excited about the prospects,” said Kenneth Aldrich, chairman of ISCO. Because the LSC products involve a unique extract from living parthenogenetic stem cells, rather than “off the shelf” ingredients used by most skin care products, it takes additional time to manufacture the products.
Building inventory in advance of demand is critical to avoid disappointing customers. ISCO and LSC believe the collaboration with Mauldin will provide a much broader potential customer base and a much lower market cost per customer than the alternative marketing programs previously considered.
As a result, LSC has revised its previously announced marketing launch plans to be certain that it will have adequate product on hand to meet initial demand. The initial product offering will be to ISCO’s own database of investors and followers, originally set to launch October and now scheduled for November to coordinate with Mauldin’s timetable. That will be followed with an offering to Mauldin’s extensive subscription base and to a select market of other potential
purchasers.
Only after these initial offerings have been completed, involving a total of over 1.5 million potential customers, will more broad scale product offerings be made. “This will enable us to measure probable future demand, assure our loyal investors and Mauldin’s subscribers and affiliates that they will be able to purchase all the products they require while allowing LSC to build an inventory of the unique stem cell extract that is at the heart of this new product,” said Dr. Ruslan Semechkin, CEO of Lifeline Skin Care.
“We are extraordinarily excited to be able to offer LSC’s products to our loyal client base in a way that assures they will be able to obtain the product they want, plus monthly refills as required, in spite of the fact that LSC’s products are unique and require time and care by many people to bring to market,” said John Mauldin, founder and chairman of Millennium. “This is a truly revolutionary approach to skin care.
Early test results are very promising and I am excited to be associated with a company of the scientific reputation of International Stem Cell Corporation and their world-renowned staff.”
International Stem Cell Corporation is a California-based biotechnology company focused on therapeutic and research products.